Form 4: Immix Biopharma Director Nancy Chang Receives Equity Grant

Director Nancy T. Chang was granted 6,250 restricted stock units and 12,500 stock options as part of the company's 2021 Equity Incentive Plan.

Summary

• Director Nancy T. Chang received a grant of 6,250 restricted stock units (RSUs) on May 22, 2026.
• The director was also granted 12,500 stock options with an exercise price of $8.78 per share.
• The RSUs vest on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.
• The stock options vest in equal monthly installments over 12 months, subject to continued service.
• Following these transactions, the director holds 428,190 shares directly and is associated with 496,940 shares held by Robinhood II, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedules ensure continued commitment from board leadership.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though the scale is relatively minor.

Risks

• Continued service requirements for vesting create dependency on the director's ongoing tenure.
• Market price volatility could impact the future value of the granted options.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing strictly on director compensation and equity holdings.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of experienced leadership.

Comparison to Industry Standards

• The use of a 2021 Equity Incentive Plan is consistent with standard corporate governance practices for small-cap biotech firms.
• Vesting schedules tied to annual meetings or one-year anniversaries align with typical industry benchmarks for director compensation.

Corporate Governance

Related Party Transactions

• The reporting person is the general manager of Robinhood II, LP, which holds 496,940 shares of the issuer.

Stakeholder Impact

• Shareholders may see minor dilution from the issuance of new equity, though this is standard for director compensation.

Next Steps

• Vesting of 6,250 RSUs on the earlier of May 22, 2027, or the 2027 Annual Meeting.
• Monthly vesting of 12,500 stock options over the next 12 months.

Key Dates

Keywords

Immix Biopharma, IMMX, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4